Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLG561 Monotherapy and Combination with Tesidolumab in Geographic Atrophy
NCT02515942Phase 2Completed
- Sponsor
- Alcon Inc.
- Start
- Sep 2015
- Primary completion
- Aug 2017
- Modality
- Antibody Conjugates, Fab Fragments, Monoclonal Antibodies
01
Overview
Phase 2, randomised, single-blind trial of CLG561 in geographic atrophy (GA), sponsored by Alcon Inc. Primary endpoints: Number of Subjects With a Serious Adverse Event That, in the Opinion of the Investigator, is Related to the Study Drug at Day 421, Mean Change From Baseline in Intraocular Pressure (IOP) at Day 309 and 1 more. Started Sep 2015; status: completed.
02
Drugs
CLG561
03
Conditions
geographic atrophy (GA)
Beyond the preview
Go deeper on NCT02515942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02515942.